Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for biologics
EPO pharma case law trends 2025: Antibodies and biologics EPO pharma case law trends 2025: Antibodies and biologics Reviewed by Dr Rose Hughes on Monday, November 17, 2025 Rating: 5
Takeda v Roche: "Is it plausible? Is it true?" Takeda v Roche: "Is it plausible? Is it true?" Reviewed by Dr Rose Hughes on Thursday, August 01, 2019 Rating: 5
SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) Reviewed by Dr Rose Hughes on Friday, June 28, 2019 Rating: 5
Roche shields itself from a UK Arrow: Pfizer v Roche Roche shields itself from a UK Arrow: Pfizer v Roche Reviewed by Dr Rose Hughes on Thursday, June 27, 2019 Rating: 5
Fordham 27 (Report 9): Biologics and Biosimilars Fordham 27 (Report 9): Biologics and Biosimilars Reviewed by Annsley Merelle Ward on Sunday, April 28, 2019 Rating: 5
Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars Reviewed by Annsley Merelle Ward on Sunday, March 12, 2017 Rating: 5
The Evolution of U.S. Law and the Bio-Pharmaceutical Industry The Evolution of U.S. Law and the Bio-Pharmaceutical Industry Reviewed by Mike Mireles on Wednesday, April 06, 2016 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.